Compare · JNJ vs PLRZ
JNJ vs PLRZ
Side-by-side comparison of Johnson & Johnson (JNJ) and Polyrizon Ltd. (PLRZ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both JNJ and PLRZ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $611.07B, about 23733.5x PLRZ ($25.7M).
- Over the past year, JNJ is up 63.6% and PLRZ is up 144.8% - PLRZ leads by 81.2 points.
- JNJ has been more active in the news (8 items in the past 4 weeks vs 5 for PLRZ).
- JNJ has more recent analyst coverage (25 ratings vs 0 for PLRZ).
- Company
- Johnson & Johnson
- Polyrizon Ltd.
- Price
- $253.77-1.59%
- $14.98+8.99%
- Market cap
- $611.07B
- $25.7M
- 1M return
- +6.49%
- +13.31%
- 1Y return
- +63.59%
- +144.77%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2024
- News (4w)
- 8
- 5
- Recent ratings
- 25
- 0
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest JNJ
- Johnson & Johnson filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2026
- Johnson & Johnson reports Q2 2026 results, raises 2026 outlook
- Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform
- Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
- Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis
- SEC Form 11-K filed by Johnson & Johnson
- SEC Form 11-K filed by Johnson & Johnson
- Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida
- New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma
Latest PLRZ
- SEC Form 6-K filed by Polyrizon Ltd.
- SEC Form 6-K filed by Polyrizon Ltd.
- Polyrizon Announces Successful Results for NASARIX™ Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial
- SEC Form 6-K filed by Polyrizon Ltd.
- Polyrizon Makes Strong Progress: Receives Central IRB Approval for its Allergy Blocker Clinical Trial
- SEC Form 6-K filed by Polyrizon Ltd.
- Polyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery Platform
- SEC Form 6-K filed by Polyrizon Ltd.
- Polyrizon Advances NASARIX™ Development with Key Human Study to Characterize Nasal Residence Time and Support FDA Regulatory Pathway
- SEC Form 6-K filed by Polyrizon Ltd.